MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare ...

The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

The French pharmaceutical giant is acquiring a Cambridge biotech and its rare immunology disease which is already approved in ...

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical ...

Paris: Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

The Ministry of Health is partnering with Sanofi to boost immunisation drives and public awareness from 2025-2027.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.